References
Cannavò S, Ambrosi B, Chiodini I, et al. Baseline and CRH-stimulated ACTH and cortisol levels after administration of the peroxisome proliferator-activated receptor-gamma ligand, rosiglitazone, in Cushing’s disease. J Endocrinol Invest 2004, 27: RC8–11.
Theocharis S, Margeli A, Kouraklis G. Peroxisome Proliferator Activated Receptor-Gamma Ligands as Potent Antineoplastic Agents. Curr Med Chem Anti-Cancer Agents 2003, 3: 239–51. Accepted November 8, 2004.
Heaney AP, Fernando M, Yong WH, Melmed SM. Functional PPAR-γ receptor is a novel therapeutic target for ACTH — secreting pituitary adenomas. Nat Med 2002, 8: 1281–7.
Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6 — month randomised placebo-controlled dose-response study. Diabetes Care 2000, 23: 1605–11.
Ambrosi B, Dall’Asta C, Cannavo S, et al. Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing’s disease. Eur J Endocrinol 2004, 151: 173–8.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Barbaro, D., Lapi, P., Orsini, P. et al. Pioglitazone treatment in Cushing’s disease. J Endocrinol Invest 28, 388–389 (2005). https://doi.org/10.1007/BF03347209
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03347209